ArriVent BioPharma (AVBP) Cash from Financing Activities (2023 - 2026)

ArriVent BioPharma has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $54.9 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $54.9 million, up 711.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $251.2 million (up 3158.65% YoY), and the FY2025 annual result was $203.1 million, up 8.83% from the prior year.
• Cash from Financing Activities came in at $54.9 million for Q1 2026 at ArriVent BioPharma, up from $34.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $185.6 million in Q1 2024 to a low of -$1.1 million in Q4 2023.
• The 4-year median for Cash from Financing Activities is $6.8 million (2025), against an average of $37.5 million.
• Peak annual rise in Cash from Financing Activities reached 63036.36% in 2025, while the deepest fall reached 96.36% in 2025.
• ArriVent BioPharma's Cash from Financing Activities stood at -$1.1 million in 2023, then surged by 105.2% to $55000.0 in 2024, then jumped by 63036.36% to $34.7 million in 2025, then soared by 58.02% to $54.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $54.9 million (Q1 2026), $34.7 million (Q4 2025), and $86.5 million (Q3 2025), per Business Quant data.